Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis


Efe C., Hagstrom H., Ytting H., Bhanji R. A. , Muller N. F. , Wang Q., ...Daha Fazla

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, cilt.15, sa.12, ss.1950-1957, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 15 Konu: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.cgh.2017.06.001
  • Dergi Adı: CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
  • Sayfa Sayıları: ss.1950-1957

Özet

BACKGROUND & AIMS: Predniso(lo) ne, alone or in combination with azathioprine, is the standard-of-care (SOC) therapy for autoimmune hepatitis (AIH). However, the SOC therapy is poorly tolerated or does not control disease activity in up to 20% of patients. We assessed the efficacy of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy for patients with AIH.